Clinical Trial Investigating the Combination Therapy With Luminor DCB and iVolution Stent in TASC C and D Femoropopliteal Lesions

General inclusion criteria: * Patient presenting a score from 2 to 5 following Rutherford classification * Patient is willing to comply with specified follow-up evaluations at the specified times * Patient is \>18 years old * Patient understands the nature of the procedure and provides written informed consent, prior to enrolment in the study * Patient has a projected life expectancy of at least 12 months * Prior to enrolment, the guidewire has crossed target lesion * Patient is eligible for treatment with the Luminor Paclitaxel-Eluting Peripheral Balloon Dilatation Catheter and the iVolution stent * Male, infertile female or female of child bearing potential practicing an acceptable method of birth control with a negative pregnancy test within 7 days prior to study procedure Angiographic inclusion criteria * De novo and post-percutaneous transluminal angioplasty (PTA) restenotic lesions located in the femoropopliteal arteries suitable for endovascular therapy * The target lesion is located within the native femoropopliteal artery * The length of the target lesion is ≥ 150mm and considered as TASC C or D lesion according to the TASC II classification. * The target lesion has angiographic evidence of stenosis \> 50% or occlusion which can be passed with standard guidewire manipulation * Target vessel diameter visually estimated is \>4mm and \<6.5 mm * There is angiographic evidence of at least one-vessel-runoff to the foot, irrespective of whether or not outflow was re-esta…